Vasomera, a stable, long-acting vasoactive intestinal peptide (VIP) agonist, targets G-protein-coupled VPAC2 receptors and is employed in the study of cardiomyopathy associated with dystrophinopathies [1].

Vasomera（静脉注射；7.5 μg/kg/min；单次给药）在模拟具有保持射血分数（HFpEF）心力衰竭的慢性肾功能不全高血压动物中，能够改善动脉顺应性和室-动脉耦合，并增强舒张功能指标（即，松弛性）[1]。